Back to results
US 2011/0034703 A1Published application
Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
Assigneeratiopharm GmbH
InventorsNesrin Mohamad, Roland Boese, Rüdiger Latz, Hans-Günter Striegel
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel crystal forms of Sunitinib and methods for their preparation.
Claims18
A polymorph I of Sunitinib characterized by an XRPD peak at 4.5±0.2 degrees of 2-theta or a melting point of 244±4° C.
A polymorph II of Sunitinib characterized by an XRPD peak at 3.8±0.2 degrees 2-theta or a melting point at 224±4° C.
A polymorph III of Sunitinib characterized by an XRPD peak at 6.3±0.2 degrees 2-theta or by an endothermic DSC signal at 180±4° C.
(canceled)
Dependencies are inferred from the claim text.